In the phase 3 trial evaluation of the pembrolizumab treatment effect in PD-L1 positive advanced NSCLC, patients with PD-L1 tumour proportion score (TPS) of 1% or greater were all enroled. The gene discussed is CD274; the disease is non-small cell lung carcinoma.